Guggenheim raises Vaxcyte stock price target on vaccine trial win
Guggenheim raised Vaxcyte's (PCVX) price target to $125 from $116, maintaining a Buy rating after positive Phase 3 trial results for VAX-31. The vaccine met primary endpoints against Pfizer's and Merck's vaccines. Guggenheim increased success probability to 95%. Vaxcyte's market cap is $8.4B, and its stock has risen 32% over the past year. BofA Securities lowered its target to $130, citing a revised launch year for VAX-31.
How this was made
The 30-second read
Why it matters
The Phase 3 success and higher success probability are new, material information likely to move the stock.
Market read
First report of pivotal trial results and analyst upgrade creates a clear trading catalyst for Vaxcyte.
What to watch
Potential competition from Pfizer and Merck vaccines and the impact of the revised launch year to 2029.
Background
The article reports analyst target raise and trial data for Vaxcyte, plus leadership appointments and a competing analyst's lower target.
Ticker impact
Guggenheim raised its price target on Vaxcyte to $125 after positive Phase 3 trial results for VAX-31.
likely upward pressure as market prices in the higher target and success probability.
The new Phase 3 data is a primary disclosure and analysts increased success probability, prompting a price‑target raise.
Market effects
Positive Phase 3 data may boost sentiment in the biotech and vaccine development sector.
US biotech stocks could see modest gains as investors reassess pipeline prospects.
The trial results could influence global vaccine market dynamics, especially for adult pneumococcal vaccines.
Counterpoint
If the FDA delays approval or the launch timeline slips further, the upside could be limited.
Key entities
- companyVaxcyte Inc.
Biotech company developing the VAX-31 adult pneumococcal vaccine.
- analystGuggenheim
Raised price target and increased success probability for Vaxcyte.
